Analyst Conference Summary

biotechnology

conference date: April 24, 2025 @ 5:00 AM Pacific Time
for quarter ending: March 31, 2025 (first quarter 2025, Q1)

Forward-looking statements

Overview: Revenue down y/y, GAAP earning up, but mainly due to 2024 IRPD expenses.

Basic data (GAAP):

Revenue was $11.2 billion, down 9% sequentially from $12.3 billion and down 6% from $11.9 billion year-earlier.

Net income was $2.46 billion, way up sequentially from $72 million and way, way up from negative $11.9 billion year-earlier.

EPS (earnings per share), diluted, were $1.20, up sequentially from $0.04, and up from negative $5.89 year-earlier.

Guidance:

Increased full year 2025 guidance slightly to $45.8 to $46.8 billion; non-GAAP EPS to $6.70 to $7.00. This includes about $500 million in expected benefit from foreign exchange rates.

Conference Highlights:

Chris Boerner, CEO, said "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline. We are advancing our multi-year plan to become a more agile and efficient company, while strengthening the foundation for top-tier, long-term growth. Our strategy is clear, and our actions are accelerating the delivery of transformational medicines to patients." Growth (newer) drugs did well, more than offset by older drugs subject to generic competition. Continues to look for potential drug acquisitions. Global climate, and U.S. governance, have a high degree of uncertainty going forward.

In Q1 2025 the EC approved Augtyro for ROS1-positive advanced NSCLC and also for advanced solid tumors expressing NTRK gene fusion.

In Q1 2025 Sotyktu (deucravacitinib) Phase 3 results for psoriatic arthritis were positive.

Camzyos coverage was increased by reduction of contraindications in April 2025. But the Phase 3 trial for non-obstructive hypertrophic cardiomyopathy did not meet its endpoints.

Cobenfy (KarXT), a first-in-classs M1/M4 agonist for schizophrenia was approved by the FDA in September 2024. First new drug for schizophrenia in decades. Prepping trials in other indications. Launch began in October 2024, with substantial sales in Q1 2025. However, in April 2025 reported the Phase 3 study did not reach statistical significance for adjuct treatment with atypical antipsychotic schizophrenia patients.

The FDA approved subcutaneous nivolomab (Opdivo Qvantig) with hyaluronidase combo for solid tumors post Opdivo+Yervoy combo therapy in December 2024. In April 2025 FDA aproved for first-line unresectable or metastatic hepatocellular carcinoma (HCC). Also, with Yervoy, for microsatellite instability or mismatch repair deficient colorectal cancer. The EMA recommended approval of the subcutaneous product and as a preoperative neoadjuvant treatment for resectable non-small cell lung cancer with high PD-L1 expression. In March 2025 the EU approved Opdivo plus Yervoy for first line HCC.

In March 2025 the EU approved Breyanzi for third-line follicular lymphoma.

In March 2025 the Sotyktu (deucravacitinib) Phase 3 trial data was positive for psoriatic arthritis.

But in February 2025 Opdualag failed to meet its primary endpoint in a Phase 3 trial for stage III-IV melanoma.

Non-GAAP numbers: diluted EPS $1.80, up 8% sequentially from $1.67 and up from negative $4.40 year-earlier. Net income $3.67 billion, up 8% sequentially from $3.4 billion, and up na% from negative $8.91 billion year-earlier.

Cash and equivalents ended at $12.1 billion up sequentially from $11.2 billion. Cash flow from operations $2.0 billion. Long-term debt was $46.1 billion, short term $3.6 billion. $0 billion used for stock repurchases, but $5 billion remains authorized. Plans to pay down $4 billion of debt in 2025/2026.

US revenue decreased 7% to 7.87$ billion; international down 2% to $3.33 billion.

The mid to late stage pipeline includes repotrectinib, farletuzumab exteribulin, AR-LDD, iberomide, mezigdomide, alnuctamab BCMA TCE, CC-99282, cendakimab, LPA1, and milvexian.

Cost of products sold was $3.03 billion. SG&A $1.58 billion. R&D $2.26 billion. Amortization of acquired intangible assets $830 million. Acquired IRPD $188 million. Other expense $339 million. Total expenses $8,23 billion. Operating profit $2,97 million. Tax $509 million.

Q&A selective summary:

U.S. manufacturing v. tariffs? We appreciate the efforts to enhance U.S. manufacturing, but it must be done in a thoughtful way. We hope outcome will enhance our competitiveness. We have been investing in our U.S. infrastructure for years. Tariffs, mainly on China, are reflected in the current guidance.

Cobenfy outlook? We don't expect the recent results to significantly affect sales. Our focus is to get Cobenfy in earlier lines of treatment, as a monotherapy. Multiple therapies are typically tried on patients with a history of failures on various monotherapies.

R&D? We continue to drive the internal pipeline. Recent failures will not have a significant impact on growth. Our financial position allows us to also source innovation externally. We have had 43 major approvals in the past 5 years. We plan for 10 new molecules for 30 new indications by the end of the decade, with some readouts this year and a bunch in 2026.

Cobenfy for Alzheimer's, etc.? The late data should have no impact on the Alzheimer's program, where we have earlier data. There is also a longer duration of treatment. We will initiate 7 new Phase 3 trials this year for various indications.

We have a broad manufacturing network, outside the U.S. we are not dependent on any particular nation.

Camzyos new data effect on sales? Camzyos growth remains strong. Data allows us to ease burden on clients and physician. So echo monitoring now just every 6 months.

Cobenfy prescriber base color? Launch going well, got Medicaid and Medicare coverage, making progress with private payers. Feedback on results for patients is possible. Reaching 30,000 psychiatrists is the aim of the launch. We also expect to see better gross to net in 2025.

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: